Biphenyl

Biphenyl

SCHEMBL2336844

O=[PH](Cl)Cl.c1ccc(-c2ccccc2)cc1

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.60
CYP1A2 P05177 1/20 0.50
MAPT P10636 2/20 0.43
LMNA P02545 2/20 0.43
HTT P42858 2/20 0.43
MAPK1 P28482 2/20 0.43
CYP3A4 P08684 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
NOTUM Q6P988 1/20 0.43
MMP3 P08254 1/20 0.43
BCL2L1 Q07817 1/20 0.43
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
WDR5 P61964 1/20 0.40
ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Biphenyl SCHEMBL10474290 0.88 ALDH1A1 (0.53) ALDH1A1CYP1A2MAPTLMNAHTT
Biphenyl SCHEMBL27743176 0.82 ALDH1A1 (0.75) ALDH1A1CYP1A2MAPTLMNAHTT
Biphenyl SCHEMBL9009477 0.80 ALDH1A1 (0.60) ALDH1A1CYP1A2MAPTLMNAHTT
Biphenyl SCHEMBL987489 0.80 ALDH1A1 (0.60) ALDH1A1CYP1A2MAPTLMNAHTT
Biphenyl SCHEMBL11137586 0.80 ALDH1A1 (0.60) ALDH1A1CYP1A2MAPTLMNAHTT
Biphenyl SCHEMBL27643334 0.78 ALDH1A1 (0.82) ALDH1A1CYP1A2MAPTLMNAHTT
Biphenyl SCHEMBL9388941 0.78 ALDH1A1 (0.82) ALDH1A1CYP1A2MAPK1CYP3A4TAAR1
Biphenyl SCHEMBL4002609 0.78 ALDH1A1 (1.00) ALDH1A1CYP1A2MAPTLMNAHTT
Biphenyl SCHEMBL1358618 0.78 ALDH1A1 (1.00) ALDH1A1CYP1A2MAPTLMNAHTT
Biphenyl SCHEMBL164 0.78 ALDH1A1 (1.00) ALDH1A1CYP1A2MAPTLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118380645-A Preparation of high-performance flame-retardant polyethylene oxide solid electrolyte and application of high-performance flame-retardant polyethylene oxide solid electrolyte in lithium battery 青岛科技大学 2024-07-23 CN claimed
CN-117209734-A Halogen-free flame-retardant polyester polyol, preparation method and application thereof in rigid polyurethane foam 万华化学集团股份有限公司 2023-12-12 CN claimed
US-20100046142-A1 Electrolyte ENERGY STORAGE SYSTEMS PTY LTD (AU) 2010-02-25 US claimed
EP-2005504-A1 ELECTROLYTE CAP-XX Limited (AU) 2008-12-24 EP claimed
WO-2007101303-A1 ELECTROLYTE CAP-XX LIMITED (AU) 2007-09-13 WO claimed
CN-118380645-A Preparation of high-performance flame-retardant polyethylene oxide solid electrolyte and application of high-performance flame-retardant polyethylene oxide solid electrolyte in lithium battery 青岛科技大学 2024-07-23 CN disclosed
CN-118380645-A Preparation of high-performance flame-retardant polyethylene oxide solid electrolyte and application of high-performance flame-retardant polyethylene oxide solid electrolyte in lithium battery 青岛科技大学 2024-07-23 CN disclosed
CN-117209734-A Halogen-free flame-retardant polyester polyol, preparation method and application thereof in rigid polyurethane foam 万华化学集团股份有限公司 2023-12-12 CN disclosed
CN-114478629-B Super-oxygen anion free radical near infrared fluorescent probe and preparation method and application thereof 徐州医科大学 2023-09-26 CN disclosed
US-11708341-B2 Synthesis of (S)-2-amino-4-methyl-((R)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof AMGEN INC. 2023-07-25 US disclosed
US-20210284617-A1 Synthesis of (S)-2-Amino-4-Methyl-((R)-2-Methyloxirane-2-Yl)-Pentan-1-One and Pharmaceutically Acceptable Salts Thereof AMGEN INC. 2021-09-16 US disclosed
EP-3494108-B1 SYNTHESIS OF (S)-2-AMINO-4-METHYL-1-((R)-2-METHYLOXIRANE-2-YL)-PENTAN-1-ONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AMGEN INC (US) 2020-10-28 EP disclosed
US-7312347-B2 Substituted optically active disphosphine compound TAKASAGO INTERNATIONAL CORPORATION (JP) 2007-12-25 US disclosed
US-20070073065-A1 Substituted optically active disphosphine compound TAKASAGO INTERNATIONAL CORPORATION (JP) 2007-03-29 US disclosed
US-20060030737-A1 Chiral diols, their manufacture and ligands and catalysts derived therefrom CIBA SPECIALTY CHEMICALS CORP. 2006-02-09 US disclosed
US-20050211136-A1 Non-aqueous solvent system including, acetonitrile, gamma -butyrolactone, and carbonate is selected from ethylene carbonate and propylene carbonate, capacitors and supercapacitors, for high power applications for mobile devices, particularly those using GSM (Global System for Mobile communication) ENERGY STORAGE SYSTEMS LIMITED (AU) 2005-09-29 US disclosed
EP-1546077-A2 CHIRAL DIOLS, THEIR MANUFACTURE AND LIGANDS AND CATALYSTS DERIVED THEREFROM Ciba SC Holding AG (CH) 2005-06-29 EP disclosed
EP-1488435-A1 AN ELECTROLYTE FOR AN ENERGY STORAGE DEVICE Energy Storage Systems Pty, Ltd. (AU) 2004-12-22 EP disclosed
WO-2004031109-A2 CHIRAL DIOLS, THEIR MANUFACTURE AND LIGANDS AND CATALYSTS DERIVED THEREFROM CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2004-04-15 WO disclosed
WO-2003079381-A1 AN ELECTROLYTE FOR AN ENERGY STORAGE DEVICE ENERGY STORAGE SYSTEMS PTY LTD (AU) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210284617-A1 Synthesis of (S)-2-Amino-4-Methyl-((R)-2-Methyloxirane-2-Yl)-Pentan-1-One and Pharmaceutically Acceptable Salts Thereof EPOR, KDM5A, PSMA5 ALDH1A1 800/4885CYP1A2 496/4885MAPT 4106/4885
US-20060030737-A1 Chiral diols, their manufacture and ligands and catalysts derived therefrom B2M, CYP4F11, CYP2F1 ALDH1A1 51/4885CYP1A2 27/4885MAPT 4517/4885
US-20070073065-A1 Substituted optically active disphosphine compound DHPS, DOHH, DHODH ALDH1A1 277/4885CYP1A2 316/4885MAPT 4288/4885
US-11708341-B2 Synthesis of (S)-2-amino-4-methyl-((R)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof EPOR, KDM5A, PSMA5 ALDH1A1 800/4885CYP1A2 496/4885MAPT 4106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.